Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.

about

Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.

Item

http://www.wikidata.org/entity/Q39049191

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@en

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@nl

type

Item

label

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@en

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@nl

prefLabel

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@en

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@nl

P1476

Incorporation of NLR into NIH ...... strointestinal stromal tumors.

@en

P2093

Anwei Xue

http://www.w3.org/2001/XMLSchema#string

Jiaqian Ling

http://www.w3.org/2001/XMLSchema#string

Jing Qin

http://www.w3.org/2001/XMLSchema#string

Kxuntang Shen

http://www.w3.org/2001/XMLSchema#string

Ping Shu

http://www.w3.org/2001/XMLSchema#string

Xiaodong Gao

http://www.w3.org/2001/XMLSchema#string

Xinyu Qin

http://www.w3.org/2001/XMLSchema#string

Yihong Sun

http://www.w3.org/2001/XMLSchema#string

Yingyong Hou

http://www.w3.org/2001/XMLSchema#string

Yong Fang

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer.

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.

Biology of gastrointestinal stromal tumors.

P304

179-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ABBS/GMW123

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28039147

http://www.w3.org/2001/XMLSchema#string